The majority of malaria endemic countries adopted effective artemisinin combination therapy more than three years ago, but its availability remains low in public and private sectors. Ineffective monotherapies dominate the market share in many countries, with some products costing up to 65 times the minimum daily wage.
A pooled analysis of two studies found significant improvements in pulmonary function, dyspnea, and rescue medication use when Perforomist Inhalation Solution was added to maintenance tiotropium. Patient satisfaction also increased with twice-daily Perforomist Inhalation Solution compared to ipratropium/albuterol metered-dose inhaler.
Data from two presentations will feature Perforomist Inhalation Solution, showing improved pulmonary function and dyspnea in patients with COPD when added to maintenance tiotropium. Patient satisfaction also increased in those treated with Perforomist twice daily compared to ipratropium/albuterol MDI